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Precis: This report provides practical guidance on the methods and reporting of VOI analysis
for assessing the value of research to inform decisions in different contexts.
Highlights:
• Value of Information (VOI) analysis provides a framework for quantifying the value of
acquiring additional information to reduce uncertainty in decision-making. Quantifying
the expected improvement with new information requires an assessment of the scale and
consequences of uncertainty in terms of pay-offs. Acquiring information, however, can
be costly. Therefore, the value of new information is compared to the cost of acquiring
the information to determine whether it is worthwhile.
• This report provides practical guidance on the methods and reporting of VOI analysis.
The methods are presented in generic form to allow them to be adapted to any specific
decision making context. This means that even in health care systems where economic
considerations are not explicitly incorporated into decision making, the same methods
can be applied.
• This report provides eight recommendations for good practice when planning, undertak-
ing or reviewing VOI analyses. The primary audience for the report are methodologists
and/or analysts who are responsible for undertaking VOI analysis to inform decision-
making.
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Abstract1
The allocation of health care resources among competing priorities requires an assessment2
of the expected costs and health effects of investing resources in the activities, and on the3
opportunity cost of the expenditure. To date, much effort has been devoted to assessing the4
expected costs and health effects, but there remains an important need to also reflect the con-5
sequences of uncertainty in resource allocation decisions and the value of further research to6
reduce uncertainty. Decision-making with uncertainty may turn out to be suboptimal, resulting7
in health loss. Consequently, there may be value in reducing uncertainty, through the collec-8
tion of new evidence, to better inform resource decisions. This value can be quantified using9
Value of Information (VOI) analysis. This report, from the ISPOR VOI Task Force, describes10
methods for computing four VOI measures: the Expected Value of Perfect Information (EVPI),11
Expected Value of Partial Perfect Information (EVPPI), Expected Value of Sample Information12
(EVSI) and Expected Net Benefit of Sampling (ENBS). Several methods exist for computing13
EVPPI and EVSI, and this report provides guidance on selecting the most appropriate method14
based on the features of the decision problem. The report provides a number of recommenda-15
tions for good practice when planning, undertaking or reviewing VOI analyses. The software16
needed to compute VOI is discussed, and areas for future research are highlighted.17
Keywords: value of information, value of research, decision making, study design, EVPI,18
EVPPI, EVSI, ENBS.19
Running title: Value of Information Analytical Methods.20
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Box 1: Background on the Task Force Process
The proposal to initiate an ISPOR Value of Information Good Practices Task Force was evaluated
by the ISPOR Health Science Policy Council and then recommended to the ISPOR Board of
Directors for approval. The task force was comprised of international subject matter experts
representing a diverse range of stakeholder perspectives (academia, research organizations,
government, regulatory agencies and commercial entities). The task force met approximately
every five weeks by teleconference and in person at ISPOR conferences. All task force members
reviewed many drafts of the report and provided frequent feedback in both oral and written
comments. To ensure that ISPOR Good Practices Task Force Reports are consensus reports,
findings and recommendations are presented and discussed at ISPOR conferences. In addition,
the first and final draft reports are circulated to the task force’s review group for a formal review.
All reviewer comments are considered. Comments are addressed as appropriate in subsequent
versions of the report. Most are substantive and constructive at improving the report.
21
Introduction22
Health care resource allocation decisions are made with uncertainty. Decision-makers, tasked23
with selecting among competing alternative options, need to determine the pay-offs associated24
with each option before making a choice, but these pay-offs are based on imperfect knowl-25
edge. This inevitably means that decisions based on the available information may turn out to26
be suboptimal. Suboptimal decisions can lead to unintended effects such as adverse health27
consequences to individuals, when expected benefits of an activity are not realized, and to the28
population, when the resources committed to the activity are transferred away from other activ-29
ities. Acquiring more information could reduce uncertainty and the associated consequences30
of suboptimal decision-making.31
Value of Information (VOI) analysis provides a framework for quantifying the value of acquir-32
ing additional information to reduce uncertainty in decision-making. Quantifying the expected33
improvement with new information requires an assessment of uncertainty and the scale of the34
consequences of that uncertainty in terms of pay-offs. Acquiring information, however, can35
be costly. Therefore, the value of new information is compared to the cost of acquiring the36
information to determine whether it is worthwhile.37
This report is the second report of the ISPOR Value of Information Analysis Emerging Good38
Practices Task Force. It provides details of the various methods used to assess the value39
of research, as well as practical guidance for selecting the appropriate method for the deci-40
sion problem of interest. These methods are presented in generic form to allow them to be41
adapted to any specific decision making context. The primary audience for this report are42
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methodologists and/or analysts who are responsible for undertaking VOI analysis to inform43
decision-making. It compliments the first report of the ISPOR VOI Task Force [1], which in-44
troduced the concept of VOI analysis, outlined the role of VOI for supporting different types of45
research decisions, and provided an overview of the steps for conducting and reporting VOI46
analysis.47
Characterization of uncertainty48
The outcomes of VOI analysis are always conditional on the characterization of the decision49
problem and the specification of judgements about the relevant uncertainties. This means that50
the extent to which VOI analysis is sufficient to quantify the value of further research depends51
critically on how well the uncertainties have been characterized. With this in mind, this report52
first characterizes the sources of uncertainty.53
The starting point for VOI analysis is typically a decision-analytic model that represents judge-54
ments about the relationship between outputs that are relevant for decision making (e.g., costs55
and health outcomes) and input parameters derived from clinical, epidemiological, registry,56
and/or economic studies. Uncertainty in decision-analytic models can be broadly character-57
ized as relating to either model input parameters or model structure; although this distinction58
is not always meaningful since model structural choices can be parametrized.59
Parameter uncertainty60
Decision-analytic models typically use information from a variety of sources, such as random-61
ized controlled trials (RCTs), observational studies, registries or expert opinion. Model input62
parameters usually correspond to unknown ‘population’ quantities, and finite-sized studies pro-63
vide imprecise estimates of these quantities. Uncertainty about the ‘true’ population parameter64
values is represented by probability distributions [2].65
Probability distributions should be assigned to all uncertain parameters (including those with66
little or no information from which to estimate the parameter), otherwise the parameter value67
is assumed to be known with certainty. When a model has more than one input parameter,68
careful consideration should be given to any dependencies between parameter values. If69
parameters are dependent, then judgements about the values of those parameters should be70
represented via a joint, correlated probability distribution. Guidelines exist to aid the selection71
of distributions for parameters [3].72
Statistical and methodological choices can also introduce uncertainty about parameter values73
when it is not clear which choice of method or statistical distribution is preferred. For exam-74
ple, choices made regarding methods used to synthesize data from multiple sources, type of75
survival distribution for extrapolation of study data, or weighting scheme used for pooling opin-76
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ions elicited from multiple experts [4, 5]. Uncertainty in parameter values can also arise due77
to missing data, poor quality data, and study estimates that are biased or confounded [6–9].78
When the most appropriate technique for data analysis or synthesis is unclear and choices79
or assumptions are required, the choice of technique should be parametrized and uncertainty80
about the choice included in the VOI analysis. Guidelines exist to aid characterization of un-81
certainty about methodological choice [10,11].82
Good practice recommendation 183
Uncertainty in parameter input values should be characterized using probability distri-84
butions, and any dependency between parameters represented by a joint, correlated85
probability distribution.86
Structural uncertainty87
A model’s structure relies on scientific judgements or assumptions about the underlying de-88
cision problem. As the model structure, or functional form, is an approximation of real world89
processes and relationships, the choice of model structure gives rise to structural uncertainty90
as a result of uncertain model error [2,12]. Quantifying structural uncertainty is difficult and is91
often ignored, which is equivalent to assuming that the model is perfect.92
Where possible, structural uncertainty should be characterized. Several methods for handling93
structural uncertainty have been described in the literature. These include: 1) scenario analy-94
sis (reporting of alternative models based on different plausible structural assumptions [13]); 2)95
model structure parametrization (adding parameters to the model that define alternative struc-96
tural choices [14]); 3) model averaging (weighting the outcomes from a set of plausible models97
based on fit to observed data or expert opinion [15, 16]); or 4) model discrepancy analysis98
(the direct quantification of uncertainty about the difference between the model evaluated at99
its ‘true’ input values, and the true value of the output quantity, either by calibration to external100
data or through expert elicitation [12,17]).101
Good practice recommendation 2102
Clearly describe any important model structural uncertainties. Where possible, struc-103
tural uncertainty should be quantified and included in the VOI analysis.104
Probabilistic analysis105
Once characterized, a complete assessment of uncertainty in all parameters, structural and106
analysis techniques is achieved through Monte Carlo probabilistic analysis (referred to as107
‘Probabilistic Sensitivity Analysis’ in the health economics literature). Probabilistic analysis108
is used to propagate the impact of uncertainty in model input parameters through to uncer-109
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tainty about model outputs. This involves repeatedly sampling values at random from each of110
the parameter input distributions and running the model, using the selected set of values, to111
provide a corresponding set of model outcomes of interest for each decision option being eval-112
uated. The results of many sampled simulations allows for estimation of the expected (mean)113
model outputs for each decision option and the uncertainty around these outputs [3].114
Good practice recommendation 3115
Use probabilistic analysis to provide an appropriate quantification of uncertainty in116
model outputs.117
Value of Information analysis118
Decision-making with uncertainty119
Decision-making with uncertainty involves choosing between alternative decision options based120
on imperfect information. In decision theory, a risk-neutral decision-maker would choose be-121
tween the alternative options based on the one that maximizes the expected pay-off [18].122
However, any decision made with uncertainty creates the potential for adverse consequences123
as the expected pay-off of the chosen option may not be realized in practice. Some decision-124
makers may be averse to this risk, preferring an option with a small guaranteed pay-off to an125
uncertain outcome with a larger expected pay-off [19, 20]. Careful selection of the attitude to126
risk that aligns with the decision-maker’s perspective is required for VOI analysis [21].127
In this report, VOI analysis is presented from the perspective of a risk-neutral decision-maker. It128
follows that a decision based on expectation is used to establish the decision option that offers129
maximum expected pay-off based on current knowledge. VOI analysis is used to address the130
question of whether further research is needed to reduce the uncertainty in the decision.131
Key concepts, definitions and notation132
VOI starts by assuming that a decision-maker is faced with a set of mutually exclusive decision133
options, indexed d in the decision space D. Next, it is assumed that a decision model, denoted134
U(d,θ), predicts the utility for decision option d given p uncertain parameters θ = {θ1, . . . , θp}.135
The uncertainty about the ’true’ unknown values of θ is represented by the joint probability136
distribution, π(θ).137
By specifying the model as a general utility function, the analysis can be tailored to any spe-138
cific decision-making context by choosing an appropriate utility metric. In Health Technology139
Assessment, where decision options represent alternative treatment interventions, the utility140
function is often defined as net health benefit or net monetary benefit.141
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The expected value of learning, with certainty, the ‘true’ values of all model parameters θ142
(i.e., eliminating all parameter uncertainty) is referred to as the Expected Value of Perfect143
Information (EVPI). The EVPI is equivalent to the expected costs of uncertainty associated144
with making the decision based on the current evidence.145
The expected value of acquiring new information about a subset of parameters of interest is146
used to identify the parameters that are important in driving the decision uncertainty. The set147
of parameters of interest is denoted by θi and the remaining complementary set of parameters148
by θc, such that together {θi,θc} = θ. The expected value of learning, with certainty, the149
parameters of interest θi is the Expected Value of Partial Perfect Information (EVPPI) for θi150
(also known as the Expected Value of Perfect Parameter Information).151
Perfect information about parameters is usually not achievable with a finite sample size, but it is152
possible to conduct a study to provide some information about the parameters. The expected153
value of a data collection exercise that will result in data X, where X will be informative for θi is154
referred to as the Expected Value of Sample Information (EVSI). The EVPPI for θi is an upper155
limit on the EVSI for any study that is informative about θi.156
Optimum decision option with current knowledge157
With current knowledge, the best that a risk-neutral decision-maker can do is to choose the158




where Eθ(·) represents expectation (mean) taken with respect to π(θ).160
Expected Value of Perfect Information (EVPI)161
If all uncertainty about θ could be eliminated with perfect information, the decision-maker would162
know the values of all parameters θ = θ∗ with certainty and, therefore, would choose the option163




However, when a decision is made about whether to conduct further research, θ∗ is not known.165
Therefore, the expected value of a decision when uncertainty is resolved with perfect informa-166
tion is found by averaging the maximized utility over the joint distribution of θ. This is the167




The EVPI is the difference between the expected value of a decision made with perfect infor-169
mation and the expected value of a decision made with current knowledge, i.e., the difference170
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Expected Value of Partial Perfect Information (EVPPI)172
If all uncertainty about a subset of parameters, θi, could be resolved with perfect information,173
the decision-maker would know the ‘true’ values θi = θ
∗
i with certainty when choosing be-174
tween the alternative decision options. However, the values of the remaining (complementary)175
parameters θc remain uncertain. Therefore, the decision option is selected based on the one176





where Eθc|θ∗i (·) represents expectation taken with respect to π(θc|θ
∗
i ). When the decision178
about conducting further research to provide information about these parameters is made, the179


















EVPI and EVPPI can be multiplied by the size of the beneficiary population to give population182
EV(P)PI values. The population EV(P)PI provides an expected upper bound on the value183
of further research that would eliminate uncertainty about all (or subsets of) parameters. A184
population EV(P)PI that is less than the estimated costs of any research study is a sufficient185
condition for establishing that research is not of value. A population EV(P)PI that is greater186
than the estimated cost of the research study is a necessary, but not sufficient, condition for187
establishing that research is potentially of value. In order to establish a sufficient condition for188
further research, the costs of conducting the new study must also be considered.189
Expected Value of Sample Information (EVSI)190
In the absence of perfect information, if data X were to become available the decision-maker191




However, the data X are not collected when the decision to conduct further research is made.193
Therefore, the expected value of a decision taken with sample information is obtained by aver-194



















As with EVPI and EVPPI, EVSI can be multiplied by the size of the beneficiary population to197
yield a population EVSI value.198
Expected Net Benefit of Sampling (ENBS)199
The difference between the population EVSI value and the cost of the data collection exercise200
is the Expected Net Benefit of Sampling (ENBS). The ENBS is a measure of the net value201
of any particular study. Under the assumption that the proposed study is relevant only to the202
decision problem at hand and has no wider value, then ENBS ≥ 0 is a necessary condition203
for conducting the study. The ENBS is powerful for guiding choices about study characteris-204
tics such as sample size and length of follow up, with the optimal design being the one that205
maximizes the ENBS [22,23].206
The costs of research not only include the costs of the study itself, but also the opportunity207
costs to individuals while the research is underway, e.g., some participants will receive a non-208
optimal intervention during the study [24].209
Estimation of VOI measures210
EVPI Computation211
In the simplest case of a two-decision option problem in which the difference in utility be-212
tween options is assumed to be normally distributed, an exact analytic expression for EVPI213
exists [25, 26]. However, for most problems an analytic solution cannot easily be derived, and214
sampling-based methods are required. For models that generate a non-linear relationship be-215
tween inputs and outputs, such as those for which Eθ{U(d,θ)} 6= U{d,Eθ(θ)}, a deterministic216
analysis, in which the model is evaluated at the mean values of its parameters, will gener-217








where θ(n), n = 1, . . . , N are samples drawn from the joint distribution π(θ). Monte Carlo sim-220











Expression (12) can be computed using the single set of N samples from π(θ) that are used223
to approximate the baseline expected utility of (11). Therefore, the computation of EVPI is224
a ‘single loop’ Monte Carlo scheme, and does not require additional sampling beyond that225
required for a probabilistic analysis - note that ‘loop’ here calls into mind the for-loop program-226
ming construct that is used to execute repeatedly a set of instructions. Algorithm 1 describes227
the single-loop scheme for computing EVPI.228
Algorithm 1
Single loop Monte Carlo scheme for computing EVPI
1. Sample a value from the distribution of the uncertain parameters.
2. Evaluate the utility function for each decision option using the parameter values generated
in step 1. Store the values.
3. Repeat steps 1 to 2 for N samples (e.g., 10,000). This is the probabilistic analysis sample.
4. Calculate the expected (mean) utility value of the N samples for each decision option.
5. Choose the maximum of the expected utility values in step 4 and store. This is the ex-
pected utility with current knowledge.
6. Calculate the maximum utility of the decision options for each of the N samples generated
in step 3.
7. Calculate the mean of the N maximum utilities generated in step 6. This is the expected
utility when uncertainty is resolved with perfect information.
8. Calculate the EVPI as the difference between the expected utility when uncertainty is




An analytic solution for EVPPI rarely exists and sampling-based methods are required. The231
first term in the EVPPI expression (7) contains a nested expectation, which means that the232






























For the parameters of interest, k = 1, . . . ,K samples, θ
(k)
i , are drawn from the distribution234
π(θi) in the ‘outer loop’ of simulation. An ‘inner loop’ of simulation is then used to sample from235
the complementary parameters, conditional on the value of θ
(k)
i . For the complementary pa-236
rameters, j = 1, . . . , J samples, θ
(j,k)
c , are drawn from the conditional distribution π(θc|θ
(k)
i ). If237
θi and θc are independent, then sampling from the conditional distribution π(θc|θ
(k)
i ) reduces to238




Double-loop Monte Carlo scheme for computing EVPPI
1. Sample a value from the distribution(s) of the target parameter(s) of interest.
2. Sample a value from the distributions of the remaining (‘complementary’) uncertain pa-
rameters, conditional on the value of the target parameter(s) sampled in step 1. If the
target and complementary parameters are independent, the sample for this step can be
drawn from the prior distribution of the complementary parameters.
3. Evaluate the utility function for each decision option using the parameter values generated
in steps 1 and 2, and store the resulting utility values.
4. While holding the parameter value from step 1 constant, repeat steps 2 and 3 for J sam-
ples. This represents the inner loop of simulation.
5. Calculate the mean of the utility values across all J samples for each decision option and
store.
6. Repeat steps 1 to 5 for K values from the distribution of the target parameter(s) (step 1)
and store the outputs from step 5. This represents the outer loop of simulation.
7. Calculate the mean utility for each decision option across all K samples of the output loop
stored in step 6.
8. Choose the maximum of the mean utilities calculated in step 7 and store. This is the
expected utility with current knowledge about the target parameter(s) of interest.
9. Calculate the maximum utility of the decision options (i.e., the maximum of the inner loop
means) for each of the K samples of the output stored in step 6.
10. Calculate the mean of the K maximum utility values generated in step 9. This yields
the expected utility when uncertainty is resolved with perfect information about the target
parameter(s) of interest.
11. Calculate the EVPPI as the difference between the expected utility when uncertainty is
resolved with perfect information about the parameter(s) of interest (step 10) and the ex-
pected utility with current knowledge (step 8).
241
Note that the selection of the sample size of the inner loop (J) is crucial as double-loop EVPPI242
computation can provide biased estimates when the sample size is small [27]. Nested double-243
loop sampling schemes can be computationally expensive. One of the key determinations244
for reducing the computational burden is whether the model is linear or multilinear in the245
complementary parameters θc. A model is linear in complementary parameters, θc1 and θc2 , if246
it can be written as a sum of these parameters, e.g., U(θ) = θc1θ
2
i1
+ θc2θi2 , where θi1 and θi2247
are parameters of interest. A model is multilinear in the complementary parameters if it can be248




If these conditions hold (and there is no correlation between the complementary parameters250
that are multiplied together), the double loop sampling scheme can be replaced by a single251
loop, where the mean values of the complementary parameters are used to avoid the need for252
the inner loop of simulation.253
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The general forms of model for which a single-loop approach is justified are described else-254
where [28]. Where applicable, single loop methods are to be preferred to reduce Monte Carlo255
error [27, 29, 30]. Algorithm 3 describes the single-loop Monte Carlo scheme for estimating256
EVPPI.257
Algorithm 3
Single-loop Monte Carlo scheme for computing EVPPI
1. Sample a value from the distribution of the target parameter(s) of interest.
2. Evaluate the utility function for each decision option using the value for the target pa-
rameter(s) from step 1 and the mean values of the remaining uncertain parameters (or
functions of them [28]). Store the values.
3. Repeat steps 1 and 2 for N samples.
4. Calculate the mean of the N utility values for each decision option.
5. Follow steps 5-8 of the algorithm for computing EVPI (algorithm 1).
258
EVPPI can also be computed using a regression-based method that uses a non-parametric,259
or other flexible regression, method to estimate the inner expectation of expression (6). The260
regression-based method only requires the single set of samples that is generated by the261
probabilistic analysis. Algorithm 4 describes the single-loop regression-based scheme for es-262
timating EVPPI.263
Algorithm 4
Single-loop regression-based scheme for computing EVPPI
1. Generate the probabilistic analysis sample using steps 1-3 of the algorithm for computing
EVPI (algorithm 1).
2. For each of the decision options, regress the estimates of utility on the parameter values
of the target parameter(s) of interest.
3. Calculate the regression fitted values for each decision option.
4. Follow steps 5-8 of the algorithm for computing EVPI (algorithm 1).
264
A review of alternative methods for computing EVPPI is available elsewhere [31], while Figure265
1 of the supplementary appendix provides guidance on the choice of computation method266
based on model features.267
Good practice recommendation 4268
When using the nested double-loop method to compute EVPPI, choose inner and outer269
loop simulation sizes to ensure acceptable bias and precision.270
Good practice recommendation 5271
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When using the single-loop methods to compute EVPPI, check that the underlying as-272
sumptions of the method hold.273
EVSI Computation274
EVSI can be computed analytically if the difference in utility between decision options is as-275
sumed to be normally distributed, and the proposed data collection exercise is expected to276
lead to a known reduction in the variance of the incremental utility [26, 32]. However, an an-277
alytic solution cannot easily be derived for most problems and sampling-based methods are278
usually required.279
For sampling-based methods, EVSI relies on the generation of plausible datasets from a pro-280
posed new study. The parameters θ can usually be partitioned into two sets: a set, θi, for281
which judgements will be informed by the newly collected data, X, and a complementary282
set θc such that {θi,θc} = θ. Plausible datasets can be obtained by first sampling values283
θ
(k)
i , k = 1, . . . ,K from the prior distribution of the model parameters π(θi). Then, conditional284
on each value θ
(k)
i , a sample from the ‘likelihood function’ (i.e., the probability distribution for285
new data, conditional on the parameters) X(k) ∼ π(X|θ
(k)
i ) is generated. The two sources of286
information are then combined to form a posterior distribution for the model parameters given287
the new sample data and the prior knowledge about the model parameters.288
When defining the likelihood for data generation, consideration should be given to how the data289
from the study would actually be analysed in the study in order to inform parameters π(θi). For290
example, the likelihood that is expected to be used in the statistical analysis of the data would291
be a naturally good candidate for the likelihood used to generate plausible datasets. The292
analyst should also consider any mechanisms that may result in corrupted, biased or missing293
(e.g. censored) data.294
When the likelihood is chosen such that the updated posterior distribution is in the same family295
as the prior (e.g., a beta prior updated by binomially distributed data results in a beta posterior)296
the prior is called a conjugate prior for the likelihood function. Conjugacy has computational297
advantages because it results in a known posterior distribution that is easy to sample from.298
The likelihood function that results in conjugacy is often (but not always) the natural choice for299
the data generating mechanism.300
The first term in the EVSI expression contains a nested expectation, which means that the301


























where parameters θ(j,k), j = 1, . . . , J are sampled from the posterior distribution π(θ|X(k)) in303
an inner loop, conditional on samples X(k), k = 1, . . . ,K in an outer loop.304
15
Algorithm 5 describes the double loop Monte Carlo scheme for estimating EVSI.305
Algorithm 5
Double-loop Monte Carlo scheme for computing EVSI
1. Define the proposed study design (sample size, length of follow-up etc). Determine the
data generating distribution (the likelihood) under this design.
2. Sample a value from the prior distribution of the parameter(s) that will be informed by new
data.
3. Sample a plausible dataset from the distribution defined in step 1, conditional on the value
of the target parameter(s) sampled in step 2.
4. Update the prior distribution of the target parameter(s) with the plausible dataset from step
3 to form the posterior distribution for the target parameter(s). Sample a value from this
posterior distribution, which may require Markov chain Monte Carlo sampling if the prior
and likelihood are not conjugate.
5. Sample a value from the prior distribution of the remaining uncertain parameters.
6. Evaluate the utility function for each decision option using the parameter values from steps
4 and 5 and store the results.
7. Repeat steps 4 to 6 J times. This represents the inner loop of simulation.
8. Calculate the mean of the utility values across all J samples for each decision option in
step 7 and store.
9. Repeat steps 2 to 8 for K values from the prior distribution of the parameters. This repre-
sents the outer loop of simulation.
10. Calculate the mean utility values for each decision option across all K samples of the
output stored in step 9.
11. Choose the maximum of the expected utility values in step 10 and store. This is the
expected utility with current knowledge.
12. Calculate the maximum utility of the decision options (i.e. the maximum of the inner loop
means) for each of the K samples of the output stored in step 9.
13. Calculate the mean of the K maximum utility values generated in step 12. This is the
expected utility with new sample information about the target parameter(s) of interest.
14. Calculate the EVSI as the difference between the expected utility with new sample infor-
mation (step 13) and the expected utility with current knowledge (step 11).
15. Repeat steps 1-14 to calculate EVSI for different study designs (e.g., studies with different
sample sizes or lengths of follow-up).
306
As with EVPPI, one of the key determinations for reducing the computation of EVSI is whether307
the model is linear or multilinear in either θi or θc (or both). For EVSI, the computation can308
also be reduced if an analytic expression exists for the posterior mean Eθi|X(θi) given the new309
data. If these conditions hold, the double loop scheme can be replaced with a single loop in310
which the mean values for the posterior distribution for the parameter(s) of interest are used311




Single loop Monte Carlo scheme for computing EVSI
1. Define the proposed study design (sample size, length of follow-up etc). Determine the
data generating distribution (the likelihood) under this design.
2. Sample a value from the prior distribution of the parameter(s) that will be informed by new
data.
3. Sample a plausible dataset from the distribution defined in step 1, conditional on the value
of the parameter(s) sampled in step 2.
4. Update the prior distribution of the target parameter(s) of interest with the new data in step
3 to form the posterior distribution. Analytically compute the expectation (mean value) of
this posterior distribution. This will be possible if the prior and likelihood distributions are
conjugate.
5. Evaluate the utility function for each decision option using the posterior mean estimate
of the target parameter(s) and the mean values of the remaining uncertain parameters.
Store the values.
6. Repeat steps 2 to 5 for N samples from the prior distribution of the target parameter(s) of
interest.
7. Calculate the mean utility values for each decision option across all N samples of the
output stored in step 5.
8. Choose the maximum of the expected utility in step 7 and store. This is the expected utility
with current knowledge about the target parameter(s) of interest.
9. Calculate the maximum utility of the decision options for each of the N samples of the
output stored in step 5.
10. Calculate the mean of the N maximum utility values generated in step 9. This is the
expected utility with new sample information about the target parameter(s) of interest.
11. Calculate the EVSI as the difference between the expected utility with new sample infor-
mation (step 10) and the expected utility with current knowledge (step 8).
12. Repeat steps 1-11 to calculate EVSI for different study designs (e.g., studies with different
sample sizes or lengths of follow-up).
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Several other methods for computing EVSI exist. As with EVPPI, EVSI can be computed315
directly from the probabilistic analysis sample using regression-based methods [30, 35]. A316
non-parametric regression is used to estimate the inner expectation of the first term of the317
EVSI expression (10), and the method becomes a single loop. The method relies on there318
being a low dimensional summary statistic for the new data s(X), a good choice being the319
summary statistic that would be reported if the study was actually conducted. The method320
makes the assumption that the relationship between s(X) and the conditional expectation321
Eθ|s(X){U(d,θ)} is smooth, which is likely to be a reasonable assumption in most models.322
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EVSI can also be approximated using importance sampling, with only a single set of prior323
parameter samples and the corresponding probabilistic analysis sample [36]. This requires324
repeated evaluation of the likelihood function, and the scheme is expected to be most use-325
ful when the utility function is computationally expensive compared to the likelihood function.326
More recently, a Gaussian approximation method, which has similarities to the regression-327
based scheme, and a moment matching method have been proposed [37, 38]. These meth-328
ods have the advantage that, once the EVSI has been computed for a single proposed study,329
the EVSI values for a range of different study sample sizes can be easily computed. Given330
the different methods available for computing EVSI, Figure 2 of the supplementary appendix331
provides guidance on the choice of EVSI computation method based on model features.332
Good practice recommendation 6333
Choose the data generating distribution for the EVSI computation to reflect how the334
data would be analysed if the proposed new study were conducted.335
Good practice recommendation 7336
When simulating datasets, model the processes that are expected to result in censoring,337
missing data and measurement bias in order to mimic the true data generating process.338
Reporting of results339
Information generated by research is used to inform decisions for the population of individuals340
who could potentially benefit from the information. This depends on the size of the beneficiary341
population whose decision choice will be informed by the additional research (e.g., the preva-342
lent cohort with the disease and/or the future incident cohort) and on the time horizon over343
which the information generated by research is useful. The VOI population estimate is deter-344
mined by multiplying the per-person VOI estimate by the size of the beneficiary population over345
the anticipated time horizon:346







where It is the incidence in time period t, T is the time horizon, and d is the discount rate for a347
single time period [39].348
An estimate of the size of the beneficiary population is typically derived from epidemiological349
data. The benefits of future research are only realized when the study findings are reported350
[26]. However, some study participants who are enrolled in the optimal arm of a research351
study will also receive the benefits of the optimal intervention while the study is conducted352
[24]. The size of the beneficiary population also depends on the perspective of the study and353
18
whether information might be generalizable to multiple jurisdictions [40]. Gradual uptake or354
implementation of research findings should also be considered when determining the size of355
the relevant population [41].356
Estimating the time horizon, T , over which the additional evidence remains informative is more357
challenging. Information generated by research is not valuable indefinitely because future358
changes are expected to occur over time that impact on the value of information [39,42]. The359
impact of these complex and uncertain processes is impossible to quantify with certainty, but360
some assessment is possible based on historical evidence and anticipated future changes,361
e.g., patent expiration, upcoming innovations, and other evaluative research underway. The362
value of research should also be discounted over this time horizon so that more weight is363
given to decisions that are informed by the research in the near term and less weight given to364
decisions informed in the more distant future.365
VOI is expressed in units of utility, which is typically net health benefit or net monetary benefit366
when a cost-effectiveness model has been employed. Because both net health and mone-367
tary benefit depend on the valuation of health opportunity cost (as expressed by the cost-368
effectiveness threshold), VOI should be reported for explicit thresholds of interest, or presented369
in graphical form as a function of the cost-effectiveness threshold. Figure 3 of the supplemen-370
tary appendix illustrates the presentation of EV(P)PI.371
Population EVSI should be reported in a similar way to EV(P)PI, but with the additional report-372
ing of information governing the research design, e.g., sample size, allocation of participants373
within the study, length of follow-up, endpoints included in the design. This includes the report-374
ing of the parameter prior distribution and likelihood function used to estimate EVSI. The costs375
of collecting the sample information should be clearly reported for the calculation of ENBS.376
This includes the fixed cost of the proposed research, the variable costs associated with the377
study design, and the expected opportunity costs while the research is underway [24]. Figure378
4 of the supplementary appendix illustrates the presentation of EVSI and ENBS.379
Good practice recommendation 8380
When reporting VOI results, clearly state all underlying assumptions.381
Other modeling considerations382
Minimal modeling383
Most commonly VOI analysis is applied when a decision-analytic model is available to charac-384
terize uncertainty and the need for further evaluative research. However, many organizations385
responsible for making research prioritization decisions lack the time and resources to under-386
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take formal decision modeling. In these circumstances, it may be necessary to adopt a minimal387
modeling approach, which allows for rapid estimation of the value of further research without388
the need for constructing a full disease and/or decision-analytic model [43,44].389
Minimal modeling may be used as a substitute for full modeling when a clinical study is avail-390
able that directly characterizes uncertainty in comprehensive measures of outcome that are391
sufficient to inform the decision maker’s utility for all relevant decision options [43]. This is392
possible when:393
• The clinical study captures all important differences in outcomes between the decision394
options being evaluated;395
• The endpoints that are important for the decision occur during the study;396
• No age-specific competing causes of death or other events occur after the study ends.397
Clinical studies that report intermediate endpoints are also amenable to minimal modeling if398
intermediate outcomes can be mapped to comprehensive outcome measures using a simple399
model with a few parameters.400
Minimal modeling offers a practical means for estimating the value of further research quickly,401
and offers a transparent and efficient method for setting research priorities [43,44]. However, it402
has a number of notable limitations. First, minimal modeling may involve an over-simplification403
of complex clinical processes. The extent to which the approach adequately addresses the404
decision problem is important, and the analyst should make clear all the assumptions un-405
derpinning the analysis. Second, the EVPPI cannot be computed for quantities that are not406
parametrized within the model. Third, it is difficult to adapt a minimal model that is based on a407
specific study to address a different, but related decision problem [43].408
VOI for endpoints other than cost-effectiveness409
Some decision-making bodies exclude economic considerations from their decision-making410
process and, instead, use a utility function based on health outcomes alone. VOI analysis may411
be applied directly to the results of standard meta-analysis (or a single study) on a specific412
outcome measure [45, 46]. This approach places the focus on an endpoint of interest, e.g.,413
distribution of values describing uncertainty about the relative effect of an intervention on mor-414
tality. The VOI is then estimated in terms of that endpoint, e.g., number of deaths avoided.415
However, it does lead to difficulty in interpreting VOI outcomes across diverse decision prob-416
lems.417
Importantly, VOI analysis is relevant to different types of health care systems and decision-418
making contexts. It should not be regarded as restricted to situations where decision-analytic419
models or estimates of cost-effectiveness are available.420
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Software resources421
Decision-analytic models are implemented in a range of software, including spreadsheets,422
modeling programs such as TreeAge (TreeAge Software, Inc., Williamstown, MA, USA) or423
SIMUL8 (SIMUL8 Corporation, Boston, MA, USA), statistical environments such as R or Stata424
(StataCorp LLC, TX, USA), or general purpose programming languages such as Python or425
C++. Whether or not the VOI analysis can be conducted using the same software as that426
used to implement the decision-analytic model will depend on the choice of VOI computation427
method.428
Compared with spreadsheets (which are noted for their perceived transparency), programming429
languages provide faster execution times and vastly increased flexibility. The analyst must430
write code, but many programming languages have specialist libraries that can reduce this431
burden (e.g. the BCEA [47] and heemod [48] packages in R). Analysts can also use web tools432
such as the Sheffield Accelerated Value of Information (SAVI) app [49] and BCEAweb [47,50],433
an online version of the BCEA R package. The introduction of these software solutions have434
allowed VOI analysis to be computed quickly; however, the analyst should always ensure that435
the underlying assumptions of the methods hold when using and interpreting the results.436
Future research directions437
The following areas have been identified where future research in VOI is warranted:438
Optimising the value of research to reduce structural uncertainties. Structural uncertainty is439
rarely quantified in model-based analysis. Not quantifying structural uncertainty implies that440
the model is a perfect representation of real world processes and relationships. VOI analysis441
for structural uncertainty has been explored previously in [12] and [14], but methods in this442
area are underdeveloped.443
Optimising study design. The set of potential study designs for a given research problem may444
be large. The design space may contain a range of sample sizes, allocations across treatment445
arms, follow-up duration, stopping rules, etc. [22]. Calculating EVSI for every combination of446
designs is likely to be computationally demanding [51], and methods are needed to increase447
computational efficiency. A related challenge is EVSI computation for trials with adaptive de-448
signs, in which aspects of the trial design itself are conditional on the data simulated in the449
EVSI calculation. The sequence in which different types of research studies should be con-450
ducted also represents an area that has received little attention to date [52].451
Computation of EVSI in complex modeling settings. When evidence from a new research452
study informs functions of model parameters, more complex situations are created, which453
increase the computational burden. Complex modeling situations arise from dynamic trans-454
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mission modeling. EVSI computation also relies on the ability to generate plausible datasets455
from a distribution that reflects the data generating process. This can be difficult if the process456
is complex (e.g., when there is bias, censoring, missingness, data corruption or measurement457
error).458
Identifying the appropriate time horizon for VOI. The ‘correct’ time horizon for research de-459
cisions (expression 15) is unknown since it is a proxy for uncertain future changes [39, 42].460
Identifying the appropriate time horizon for research decisions and incorporating uncertainty461
in the time horizon is an area that has received little attention to date.462
Conclusions463
This, second, report of the ISPOR VOI Task Force provides good practice guidance in the464
form of detailed algorithms for estimating EVPI, EVPPI and EVSI. It also provides information465
about efficient approaches and software available to support the implementation of VOI. Box 2466
provides a summary of the good practice recommendations, for conducting and reviewing VOI467
analyses, presented throughout this report.468
Box 2: ISPOR Value of Information Analysis Task Force Report’s Good Practice
Recommendations for Conducting and Reporting a VOI analysis
1. Uncertainty in parameter input values should be characterized using probability distribu-
tions, and any dependency between parameters represented by a joint, correlated proba-
bility distribution.
2. Clearly describe any important model structural uncertainties. Where possible, structural
uncertainty should be quantified and included in the VOI analysis.
3. Use probabilistic analysis to provide an appropriate quantification of uncertainty in model
outputs.
4. When using the nested double-loop method to compute EVPPI, choose inner and outer
loop simulation sizes to ensure acceptable bias and precision.
5. When using the single-loop methods to compute EVPPI, check that the underlying as-
sumptions of the method hold.
6. Choose the data generating distribution for the EVSI computation to reflect how the data
would be analysed if the proposed new study were conducted.
7. When simulating datasets, model the processes that are expected to result in censoring,
missing data and measurement bias in order to mimic the true data generating process.
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Supplementary Appendix616
Model is multilinear in θc
AND
Parameters within any multiplica-
tive set within θc are independent
AND
Independence between θi and θc
The model can be
re-parametrized so that it
is multilinear in θc
AND
Independence between θi and θc
The model is non-linear in θc
but there is a Taylor Series
approximation for the expectation
of the non-linear function of θc
AND
Independence between θi and θc
The model is non-linear in θc
but there is a spline-based
approximation to the expectation
of the non-linear function of θc
The model is computationally
cheap to conduct with an accept-
able level of Monte Carlo error
Utility is a well-specified
smooth function of the
parameters of interest
Single-loop Monte Carlo scheme
Methods 1 & 2 in [28]
See Algorithm 3
Single-loop Monte Carlo scheme
Method 3 in [28]
See Algorithm 3
Single-loop Monte Carlo scheme
Method 4 in [28]
See Algorithm 3
Single-loop Monte Carlo scheme
Method 5 in [28]
See Algorithm 3
Double-loop Monte Carlo scheme






Double-loop Monte Carlo scheme
Box 1 in [53].
Carefully consider min-














Figure 1: Process for choosing a method for computing the Expected Value of Partial Perfect
Information based on model features. Algorithm numbers refer to algorithms in this report.
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Model is multilinear
in all the parameters
AND
Parameters within any multi-
plicative set are independent
AND




The model is multilinear
in θi or θi but not both
OR
The model is multilinear in all pa-
rameters, but no analytic expres-
sion for posterior mean E(θi|X)





Sampling from the posterior
π(θi|X) is straightforward
The model is of arbitrary form
AND
Evaluating the likelihood is
straightforward
Each simulated dataset, X,
can be summarized with a low
dimensional summary statistic
Single-loop Monte Carlo scheme













mation’ method [37] or ‘mo-











Figure 2: Process for choosing a method for computing the Expceted Value of Sample Infor-
mation based on model features. Algorithm numbers refer to algorithms in this report.
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Figure 3: An illustration of population Expected Value of Perfect Information (EVPI) for all
model parameters and Expected Value of Partial Perfect Information (EVPPI) for two specific
parameters of interest, over a range of cost-effectiveness thresholds. The higher the EV(P)PI,
the larger the opportunity cost of a suboptimal decision. The EV(P)PI falls as one decision
option appears increasingly optimal, i.e., as the probability of error falls. Additional research
should only be considered if the EV(P)PI exceeds the expected cost of the research. In this
example, the EVPI exceeds the cost of research between the cost-effectiveness thresholds of
$19,000 and $38,000 per quality-adjusted life year (QALY).
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Figure 4: An illustration of population Expected Value of Sample Information (EVSI) and Ex-
pected Net Benefit of Sampling (ENBS) for a range of sample sizes of research study. The
EVSI increases with the sample size but at a declining rate. In this example, the marginal
costs of sampling are constant, as shown by the line indicating the cost of research study. The
ENBS reaches a maximum at an optimal sample size of 170.
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